July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The SWIM 2 (Switching from Intermittent Anti-VEGF to Monthly Therapy in Neovascular AMD) Study
Author Affiliations & Notes
  • Kellen Kashiwa
    Retina Institute of Hawaii, Honolulu, Hawaii, United States
  • Michael Bennett
    Retina Institute of Hawaii, Honolulu, Hawaii, United States
  • Claudia Hooten
    Retina Institute of Hawaii, Honolulu, Hawaii, United States
  • Kent Demaine
    Retina Metrics, LLC, Los Angeles, California, United States
  • Christopher Milroy
    Engility, Chantilly, Virginia, United States
  • Bryn Stark
    Engility, Chantilly, Virginia, United States
  • Footnotes
    Commercial Relationships   Kellen Kashiwa, None; Michael Bennett, None; Claudia Hooten, None; Kent Demaine, None; Christopher Milroy, None; Bryn Stark, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2374. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kellen Kashiwa, Michael Bennett, Claudia Hooten, Kent Demaine, Christopher Milroy, Bryn Stark; The SWIM 2 (Switching from Intermittent Anti-VEGF to Monthly Therapy in Neovascular AMD) Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2374.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effectiveness and determine if an Artificial Intelligent (AI)/ machine learning (ML) platform can learn and recognize OCT changes in patients in patients with Wet Age Related Macular degeneration.

Methods : This is an ongoing phase 2 analytic study of the Retina Metrics- Synthetic Analyst AI platform. 200 patients with neovascular AMD were primarily enrolled. Patients were eligible if they had received ≥3 doses of anti-VEGF therapy pro re nata (PRN) in the preceding 18 months. Changes in VA (Early Treatment Diabetic Retinopathy Study [ETDRS] letters), central foveal thickness (CFT), fluorescein leakage, and resolution of macular edema are assessed. The last-observation-carried-forward method is used to impute missing data. Safety monitoring includes monthly evaluation of ocular and systemic adverse events.

Results : Results: Of 200 patients, changes in VA, IOP, CFT were mapped, time stamped and followed. The Retina Metrics – Synthetic Analyst platform was used to analyze, assess, interpret and potentially learn the associated clinical numeric and image findings. From baseline to date, (n=100) CFT improved by a mean (± SEM) of 39.0 ± 6.8 and 44.5 ± 7.0 mm at months 6 and 12, respectively. At study month 12, compared with baseline: in patients previously treated for <12 months (n=26) VA improved from 47.6 to 52.5 letters; in patients previously treated for 12 to 18 months (n=30) VA improved from 52.7 to 59.5 letters; and in patients previously treated for >18 months (n = 65) VA improved from 35.2 to 40.5 letters. One patient experienced a transient ischemic attack, and 1 had a retinal tear prior to month 6.

Conclusions : Monthly Anti VEGF therapy improved VA and CFT in neovascular AMD patients who received prior PRN anti-VEGF therapy. The Synthetic Analyst AI Platform, had the ability to map and identify the both the image changes and quasi-Image changes associated within this complex patient population. Patients previously treated for >18 months with anti-VEGF therapy had worse baseline VA and final VA after Anti-VEGF therapy compared with patients previously treated for ≤18 months. With further Machine learning, the AI platform may not only be able to identify clinical changes, but it may be able to suggest a patient specific regimen aimed at improving visual acuity (VA) and anatomic outcomes in patients with neovascular age-related macular degeneration (AMD).

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×